Catalyst Dossier · compiled by CeliA 🧫
NOVO NORDISK A S (NONOF)
Biotechnology · market cap $215.0B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-25 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Novo Nordisk A/S (NONOF) is a large-cap Danish biotechnology/pharmaceutical company with approximately 68,794 employees and a market capitalization of roughly $215 billion. The company operates a broad pipeline spanning diabetes, obesity, haemophilia, cardiovascular risk, and rare diseases, anchored by established franchises in insulin and GLP-1 therapies. Key near-term catalysts are concentrated in Ziltivekimab (cardiovascular risk, Phase 3 readouts estimated October and December 2026) and Cagrilintide (obesity, Phase 3 readout estimated May 2027).
The catalyst path
- 2027-01-25 (est.)Phase 3 · insulin aspartimp 9/10
- 2027-01-29 (est.)Phase 3 · Ziltivekimabimp 9/10
- 2027-03-01 (est.)Phase 3 · CagriSema (Cagrilintide B and Semaglutide I)imp 9/10
- 2027-05-18 (est.)Phase 3 · Cagrilintideimp 9/10
- 2027-06-14 (est.)Phase 2 · Semaglutideimp 7/10
- 2027-09-03 (est.)Phase 2 · NNC0662-0419imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| biphasic human insulin | Phase 3 | Diabetes |
| eptacog alfa (activated) | Phase 3 | Acquired Bleeding Disorder |
| recombinant interleukin-21 | Phase 2 | Cancer |
| Cagrilintide | Phase 3 | Obesity |
| insulin aspart | Phase 3 | Diabetes |
| liraglutide | Phase 3 | Diabetes |
| insulin degludec/liraglutide | Phase 3 | Diabetes |
| Mim8 | Phase 3 | Haemophilia A With or Without Inhibitors |
| rosiglitazone | Phase 3 | Diabetes |
| insulin degludec/insulin aspart | Phase 3 | Diabetes |
| Ziltivekimab | Phase 3 | Cardiovascular Risk |
| biphasic insulin aspart | Phase 3 | Diabetes |
| NNC126-0083 | Phase 2 | Growth Hormone Disorder |
| Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 |
| insulin degludec | Phase 3 | Diabetes |
| Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 |
| catridecacog | Phase 3 | Congenital Bleeding Disorder |
| Turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder |
| Somapacitan | Phase 3 | Growth Hormone Deficiency in Children |
| insulin detemir | Phase 3 | Diabetes |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NONOF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.